Research progress on seroepidemiological study of enterovirus 71 and coxsackievirus A16 infection among children.
- Author:
Li LUO
1
;
Weijia XING
1
;
Qiaohong LIAO
1
;
Hongjie YU
2
Author Information
1. Division of Infectious Disease, Key Laboratory of Surveillance and Early-warning on Infectious Disease, Chinese Center for Disease Control and Prevention, Beijing 102206, China.
2. Division of Infectious Disease, Key Laboratory of Surveillance and Early-warning on Infectious Disease, Chinese Center for Disease Control and Prevention, Beijing 102206, China. Email: yuhj@chinacdc.cn.
- Publication Type:Journal Article
- MeSH:
Adaptive Immunity;
Adult;
Age Factors;
Antibodies, Neutralizing;
Child;
China;
Enterovirus;
Enterovirus A, Human;
Humans;
Immunity, Maternally-Acquired;
Infant;
Infant, Newborn;
Mothers;
Seroepidemiologic Studies;
Vaccination
- From:
Chinese Journal of Preventive Medicine
2015;49(2):184-188
- CountryChina
- Language:Chinese
-
Abstract:
Most common causative agents for hand, foot and mouth disease (HFMD) are enterovirus 71 (EV-A71) and coxsackievirus A16 (CV-A16). The symptomatic and asymptomatic cases could transmit the disease in population. Many sero-epidemiological surveys were launched to estimate the sero-incidence of EV-A71 and CV-A16 enterovirus, the susceptibility of different sub-population, and to observe the dynamics of neutralizing antibody. A literature search of sero-epidemiological study focused on EV-A71 or CV-A16 was conducted via PubMed and China Hospital Knowledge Database. Based on the 20 selected studies, the different age groups' antibody level, the susceptibility, the dynamics of antibody and sero-incidence of EV-A71 or CV-A16 were analyzed. From our results, the antibody level against EV-A71 or CV-A16 in neonates was associated with their mothers, which was similar with that of adults. The antibody level against EV-A71 or CV-A16 in neonates dropped to lowest level at one years-old, and started to dramatically increase until four years-old, and reached a plateau at five years-old. In conclusion, the infants aged 6-12 months were the priority group to receive vaccination when the EV-A71 vaccine is licensed in the future.
